Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China

Objective To evaluate the cost-utility of first-line zanidatamab plus chemotherapy, with or without tislelizumab, versus trastuzumab plus chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma from the Chinese healthcare-system perspective. Methods A partitioned survival model informed by HERIZON-GEA-01 was developed over a 10-year horizon. Costs and health outcomes were discounted at 4.5% annually. Base-case analysis compared costs and quality-adjusted life years (QALYs) across all three strategies and assessed incremental cost-utility. Deterministic and probabilistic sensitivity analyses assessed parameter uncertainty, including survival parameters. Scenario analyses examined alternative survival extrapolations, 5- and 15-year horizons, subsequent-treatment assumptions, adverse-event utility losses, and hypothetical patient assistance programs (PAPs). Price-threshold analyses identified the zanidatamab prices at which each strategy became preferred among all three alternatives. The primary willingness-to-pay threshold was USD 27,917.37/QALY, equivalent to twice China’s per capita GDP in 2025. Results Zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, and trastuzumab plus chemotherapy generated 2.2414, 1.7196, and 1.4737 QALYs at costs of USD 144,992.86, USD 105,313.53, and USD 29,633.07, respectively. Compared with trastuzumab plus chemotherapy, the corresponding incremental cost-utility ratios were USD 150,270.88/QALY and USD 307,767.29/QALY. Zanidatamab plus chemotherapy was subject to extended dominance. Sensitivity and scenario analyses, including the 5- and 15-year horizons, supported trastuzumab plus chemotherapy as the preferred strategy. Neither zanidatamab-containing regimen achieved positive incremental net monetary benefit in 5,000 probabilistic simulations at the primary threshold. Hypothetical PAPs reduced the pairwise incremental cost-utility ratios to USD 55,749.41/QALY and USD 106,806.31/QALY. Without PAP, simultaneous zanidatamab price reductions of approximately 76.13%–92.87% favored zanidatamab plus chemotherapy, while larger reductions favored the tislelizumab-containing regimen, with ties at boundary prices. Conclusion At the evaluated prices and primary willingness-to-pay threshold, neither zanidatamab-containing regimen was cost-effective in China. Substantial zanidatamab price reductions would be required to change the preferred strategy. Longer follow-up is needed to reassess uncertainty in long-term survival.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.3389/fphar.2026.1951956
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China

满宏伟, Liman Huo, Xiaojie Feng, Ying Zheng et al.
Frontiers in Pharmacology
Health Systems, Economic Evaluations, Quality of Life
article

Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China

满宏伟, Liman Huo, Xiaojie Feng, Ying Zheng, Yuehua Zhang, Mei Zhou, Xiaoyue Ma
article en

Abstract

Objective To evaluate the cost-utility of first-line zanidatamab plus chemotherapy, with or without tislelizumab, versus trastuzumab plus chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma from the Chinese healthcare-system perspective. Methods A partitioned survival model informed by HERIZON-GEA-01 was developed over a 10-year horizon. Costs and health outcomes were discounted at 4.5% annually. Base-case analysis compared costs and quality-adjusted life years (QALYs) across all three strategies and assessed incremental cost-utility. Deterministic and probabilistic sensitivity analyses assessed parameter uncertainty, including survival parameters. Scenario analyses examined alternative survival extrapolations, 5- and 15-year horizons, subsequent-treatment assumptions, adverse-event utility losses, and hypothetical patient assistance programs (PAPs). Price-threshold analyses identified the zanidatamab prices at which each strategy became preferred among all three alternatives. The primary willingness-to-pay threshold was USD 27,917.37/QALY, equivalent to twice China’s per capita GDP in 2025. Results Zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, and trastuzumab plus chemotherapy generated 2.2414, 1.7196, and 1.4737 QALYs at costs of USD 144,992.86, USD 105,313.53, and USD 29,633.07, respectively. Compared with trastuzumab plus chemotherapy, the corresponding incremental cost-utility ratios were USD 150,270.88/QALY and USD 307,767.29/QALY. Zanidatamab plus chemotherapy was subject to extended dominance. Sensitivity and scenario analyses, including the 5- and 15-year horizons, supported trastuzumab plus chemotherapy as the preferred strategy. Neither zanidatamab-containing regimen achieved positive incremental net monetary benefit in 5,000 probabilistic simulations at the primary threshold. Hypothetical PAPs reduced the pairwise incremental cost-utility ratios to USD 55,749.41/QALY and USD 106,806.31/QALY. Without PAP, simultaneous zanidatamab price reductions of approximately 76.13%–92.87% favored zanidatamab plus chemotherapy, while larger reductions favored the tislelizumab-containing regimen, with ties at boundary prices. Conclusion At the evaluated prices and primary willingness-to-pay threshold, neither zanidatamab-containing regimen was cost-effective in China. Substantial zanidatamab price reductions would be required to change the preferred strategy. Longer follow-up is needed to reassess uncertainty in long-term survival.

Frontiers in PharmacologyVol. 17
Fourth Hospital of Hebei Medical University (CN), People's Hospital of Cangzhou (CN)
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon